Dexcom has announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1.

Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors.  | Dexcom said Smart Basal is the ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...

"During the quarter, we delivered strong revenue results, expanded access to Dexcom G7, and introduced multiple enhancements to Dexcom’s digital platform," said Jake Leach, Dexcom’s president and ...

Two years ago, Eli Lilly started working with Dexcom to integrate continuous glucose monitoring (CGM) into its insulin delivery devices, and it has now firmed up the alliance. Lilly has taken a ...

Wells Fargo lowered the firm’s price target on DexCom (DXCM) to $93 from $98 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 sales/EPS beat driven by strong ...

Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...

Investors focused on Dexcom’s lower gross margin of 61.3%, down about 170 basis points year-over-year, despite record revenue and earnings. The company said elevated scrap and freight costs would ...

Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.